Immuron (IMRN) vs Moleculin Biotech (MBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immuron is the larger company by market cap ($9.0 million vs $8.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | IMRN | MBRX |
|---|---|---|
| Share price | $1.11 | $0.424 |
| Market cap | $8.96M | $8.64M |
| 1-day change | +1.83% | -3.39% |
| P/E ratio (TTM) | — | 0.05 |
| EPS (TTM) | $-0.34 | $8.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.39 | $15.75 |
| 52-week low | $0.677 | $0.161 |
| Distance from 52-week high | -53.56% | -97.31% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +250.45% | +2730.19% |
| Average volume | 2.06M | 1.28M |
| Shares outstanding | 8.07M | 20.39M |
| Employees | 7 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immuron
IMRN stock →Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.
Healthcare · Biotechnology · 7 employees
About Moleculin Biotech
MBRX stock →Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
Healthcare · Biotechnology · 17 employees
IMRN vs MBRX FAQ
Which is bigger, Immuron or Moleculin Biotech?
Immuron (IMRN) is larger, with a market capitalization of $8.96M compared with $8.64M for Moleculin Biotech (MBRX).
Are Immuron and Moleculin Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.